Tatva Chintan Pharma Chem Limited (TATVA) AI Stock Analysis

• Market Cap: ₹24.73B
• Dividend Yield: 0.19%
• Average Volume (3M): 24.09K
• Price to Earnings (P/E): 345.7
• Beta (1Y): 0.75
• Revenue Growth: 2.47%
• EPS Growth: -72.80%
• Country: IN
• Employees: 689
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Chemicals - Specialty
• EPS (TTM): 3.00
• Shares Outstanding: 23,392,056
• 10 Day Avg. Volume: 12,859
• 30 Day Avg. Volume: 24,091
• PEG Ratio: -3.55
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 4.33
• P/FCF Ratio: -32.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,219.00
• Price Target Upside: 17.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: ₹1,219.00 ▲(17.19% Upside)

The overall stock score for Tatva Chintan Pharma Chem Limited reflects a balanced view of its mixed financial performance and strong technical indicators. While the company's investment in future growth is promising, current cash flow challenges and high valuation raise concerns. The technical analysis indicates bullish momentum, but potential overbought conditions suggest caution. The lack of earnings call insights and notable corporate events limits additional context.

Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model

Company Description

Tatva Chintan Pharma Chem Limited (TATVA) is an Indian chemical manufacturing company that specializes in the production of a diverse range of specialty chemicals. The company operates within sectors such as pharmaceuticals, agrochemicals, personal care, and automotive, providing high-quality chemical components that are critical in various industrial applications. Tatva Chintan is known for its strong research and development capabilities, which enable it to offer innovative and customized chemical solutions to its clients.

How the Company Makes Money

Tatva Chintan Pharma Chem Limited makes money primarily through the manufacturing and sale of specialty chemicals. Its revenue model is based on providing a wide array of products that cater to different industries, including phase transfer catalysts, structure-directing agents, pharmaceutical and agrochemical intermediates, and other specialty chemicals. The company earns revenue by supplying these essential chemical components to manufacturers in the pharmaceutical, agrochemical, personal care, and automotive sectors. Additionally, Tatva Chintan's focus on research and development allows it to develop proprietary products and solutions, further enhancing its market position and profitability. Strategic partnerships and long-term relationships with clients contribute significantly to its earnings, ensuring steady demand and financial stability.

Tatva Chintan Pharma Chem Limited Financial Statement Overview

Summary

Tatva Chintan Pharma Chem Limited displays a mixed financial performance. While it has a strong balance sheet with low leverage and a solid capital base, volatility in profitability and revenue growth are concerns. Cash flow challenges, driven by significant capital expenditures, signal a need for strategic cash management. The company is investing for the future but needs to ensure that current operations are robust to support long-term growth.

Income Statement

Tatva Chintan Pharma Chem Limited exhibits a mixed performance in its income statement. The company has shown inconsistent revenue growth with a decline in revenue from 2024 to 2025, which may raise concerns. Gross Profit Margin has been strong historically but has recently declined, indicating cost pressures. The Net Profit Margin has been volatile, showing a sharp decrease in 2025, which suggests challenges in maintaining profitability. Despite these fluctuations, the company maintains positive EBIT and EBITDA margins, which reflect underlying operational efficiency.

Balance Sheet

The balance sheet of Tatva Chintan Pharma Chem Limited is solid, with a strong equity position. The Debt-to-Equity Ratio is low, indicating conservative leverage and financial stability. The Equity Ratio is robust, reflecting a strong capital base. However, the Return on Equity has decreased over time, suggesting potential inefficiencies in generating returns from equity capital. Overall, the company is financially stable, but there are areas for improvement in asset utilization.

Cash Flow

The cash flow statement reflects challenges with negative free cash flow across the years, primarily due to high capital expenditure, which may indicate investment for future growth but affects current liquidity. Operating Cash Flow to Net Income Ratio is positive, showing that operational cash generation is supporting net income. However, the Free Cash Flow to Net Income Ratio is negative, highlighting the pressure from capital outlays. The negative Free Cash Flow Growth Rate suggests a need for careful cash management moving forward.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.83B	3.83B	3.94B	4.24B	4.34B	3.00B
Gross Profit	1.84B	1.84B	2.11B	1.91B	2.32B	1.43B
EBITDA	328.97M	342.13M	689.34M	676.30M	1.08B	666.37M
Net Income	57.13M	57.13M	303.54M	454.87M	958.74M	522.62M
Balance Sheet
Total Assets	8.36B	8.36B	8.19B	7.56B	6.58B	3.15B
Cash, Cash Equivalents and Short-Term Investments	140.96M	140.96M	456.68M	480.08M	1.74B	44.81M
Total Debt	363.88M	363.88M	142.71M	1.70B	1.20B	902.48M
Total Liabilities	974.25M	974.25M	816.36M	2.42B	1.85B	1.49B
Stockholders Equity	7.39B	7.39B	7.37B	5.15B	4.73B	1.66B
Cash Flow
Free Cash Flow	0.00	-516.01M	-304.71M	-1.75B	-687.79M	33.49M
Operating Cash Flow	0.00	246.71M	980.44M	277.83M	203.78M	243.19M
Investing Cash Flow	0.00	-652.54M	-1.21B	-1.01B	-1.97B	-210.06M
Financing Cash Flow	0.00	165.66M	305.19M	377.95M	2.35B	-88.01M

Tatva Chintan Pharma Chem Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1040.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Positive. The current price of 1040.15 is below the 20-day moving average (MA) of 1053.25, above the 50-day MA of 988.68, and above the 200-day MA of 845.67, indicating a bullish trend. The MACD of 43.53 indicates Positive momentum. The RSI at 53.96 is Neutral, neither overbought nor oversold. The STOCH value of 30.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TATVA.

Tatva Chintan Pharma Chem Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FCL	72 Outperform	₹26.12B	23.92		0.35%	-8.66%	-17.63%
IOLCP	69 Neutral	₹26.49B	25.22		0.89%	2.73%	-11.40%
PUNJABCHEM	64 Neutral	₹15.51B	33.64		0.23%	9.24%	2.10%
TATVA	63 Neutral	₹24.73B	345.69		0.19%	2.47%	-72.80%
KIRIINDUS	61 Neutral	₹29.80B	15.84		―	-12.76%	-17.97%
Sector *	58 Neutral	HK$18.06B	5.29	-7.29%	3.72%	-4.08%	-48.58%
YASHO	52 Neutral	₹21.28B	167.95		0.03%	12.73%	-70.56%

Tatva Chintan Pharma Chem Limited Corporate Events

Tatva Chintan Updates RTA Contact Details

Tatva Chintan Pharma Chem Limited has announced a change in the contact details of its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The update includes new email addresses and a website for handling shareholder queries and service requests electronically, reflecting the company’s commitment to improving stakeholder communication and operational efficiency.